Mikael Roussel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mikael Roussel has a total of 559 co-authors. Here are the top co-authors by number of shared publications:
- Thierry Fest
Université de Rennes 1, INSERM, Établissement Français du Sang de Bretagne, UMR_S1236, Rennes, France
33 shared publications - Céline Pangault
UMR INSERM 1236, Université de Rennes, 1, EFS de Bretagne, CHU de Rennes, Rennes, France
14 shared publications - Thierry Lamy
Rennes University Hospital, Rennes, France
13 shared publications - Delphine Rossille
University of Rennes
11 shared publications Thierry Lamy
Rennes University Hospital, Rennes, France
11 shared publications- Noel Milpied
CHU Bordeaux, Pessac, France
10 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 6049-6050
Diagnosis of NK-Large Granular Lymphocytic Leukemia
- 30 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 6049-6050
Open AccessDiagnosis of NK-Large Granular Lymphocytic Leukemia
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Supplemental methods, tables and figures
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Supplemental methods, tables and figures
- Top Cited PapersOpen Access
- 13 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (4) , 1217-1232
Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the 2 most common B-cell lymphomas and are characterized by a dynamic crosstalk between tumor B cells and a heterogeneous, tumor-supportive microenvironment, such as immune, endothelial, and stromal components. Despite their recognized impact on the pathogenesis and prognosis of B-cell lymphoma, tumor-associated macrophages (TAM) have not been extensively explored in these diseases. In this study, we investigated mononuclear phagocyte (MNP) heterogeneity at the single-cell level and the activation profile of MNP, stromal, and endothelial compartments, in B-cell lymphoma lymph nodes compared to reactive secondary lymphoid organs. This was achieved using a combination of mass cytometry, single-cell RNA sequencing, in silico and spatial imaging approaches. Our findings revealed a lymphoma-specific pattern of TAM and blood endothelial cell (BEC) coactivation. Furthermore, we identified in DLBCL a spatial interaction between Annexin A1 (ANXA1)-expressing BEC and formyl-peptide receptor (FPR1/2) and S100A9-expressing monocytes/macrophages. This crosstalk is associated with an immunosuppressive tumor microenvironment and an adverse prognosis in patients with DLBCL.
- 13 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (4) , 1217-1232
Top Cited PapersOpen AccessMyeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the 2 most common B-cell lymphomas and are characterized by a dynamic crosstalk between tumor B cells and a heterogeneous, tumor-supportive microenvironment, such as immune, endothelial, and stromal components. Despite their recognized impact on the pathogenesis and prognosis of B-cell lymphoma, tumor-associated macrophages (TAM) have not been extensively explored in these diseases. In this study, we investigated mononuclear phagocyte (MNP) heterogeneity at the single-cell level and the activation profile of MNP, stromal, and endothelial compartments, in B-cell lymphoma lymph nodes compared to reactive secondary lymphoid organs. This was achieved using a combination of mass cytometry, single-cell RNA sequencing, in silico and spatial imaging approaches. Our findings revealed a lymphoma-specific pattern of TAM and blood endothelial cell (BEC) coactivation. Furthermore, we identified in DLBCL a spatial interaction between Annexin A1 (ANXA1)-expressing BEC and formyl-peptide receptor (FPR1/2) and S100A9-expressing monocytes/macrophages. This crosstalk is associated with an immunosuppressive tumor microenvironment and an adverse prognosis in patients with DLBCL.
- Top Cited PapersOpen Access
- 29 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 642-653
Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study
Natural killer (NK) large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative disorder lacking definitive clonality markers, complicating diagnosis and distinction from reactive NK cell expansions. We previously proposed an NK clonality score with high diagnostic accuracy, but a subset of patients remained unclassified. In this multicenter international study, we refined and validated updated diagnostic criteria using independent training (n = 78) and validation (n = 57) cohorts from 3 national registries (United States, Italy, and France). The revised framework integrates NK score parameters with CC motif chemokine ligand 22 (CCL22) mutations and bone marrow biopsy (BMB) findings. Four major criteria were defined: NK cell count of ≥1.0 × 109/L, killer-cell immunoglobulin-like receptor restriction, CD94/NKG2A overexpression, and somatic mutations in STAT3, TET2, or CCL22, the latter newly introduced. In the training cohort, 50 patients were classified as having NK-LGLL by an NK score of >4, 18 had intermediate scores (2-3), and 10 were diagnosed as reactive proliferations. CCL22 mutations were identified in 16 patients (20%), including 5 with intermediate scores who were reclassified as NK-LGLL; BMB supported the diagnosis in 2 additional cases, resulting in 57 NK-LGLL overall. These patients exhibited more cytopenias, higher treatment needs, and greater transfusion requirements than patients with alternative diagnoses. In the validation cohort (25 NK-LGLL and 32 reactive cases), CCL22 mutations were detected in 5 NK-LGLL (20%). Altogether, incorporation of CCL22 mutations reduced the fraction of unclassified patients, improved diagnostic sensitivity without compromising specificity, and may decrease reliance on invasive procedures. These revised international criteria represent a step toward standardized, molecularly guided NK-LGLL diagnosis.
- 29 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 642-653
Top Cited PapersOpen AccessDiagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study
Natural killer (NK) large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative disorder lacking definitive clonality markers, complicating diagnosis and distinction from reactive NK cell expansions. We previously proposed an NK clonality score with high diagnostic accuracy, but a subset of patients remained unclassified. In this multicenter international study, we refined and validated updated diagnostic criteria using independent training (n = 78) and validation (n = 57) cohorts from 3 national registries (United States, Italy, and France). The revised framework integrates NK score parameters with CC motif chemokine ligand 22 (CCL22) mutations and bone marrow biopsy (BMB) findings. Four major criteria were defined: NK cell count of ≥1.0 × 109/L, killer-cell immunoglobulin-like receptor restriction, CD94/NKG2A overexpression, and somatic mutations in STAT3, TET2, or CCL22, the latter newly introduced. In the training cohort, 50 patients were classified as having NK-LGLL by an NK score of >4, 18 had intermediate scores (2-3), and 10 were diagnosed as reactive proliferations. CCL22 mutations were identified in 16 patients (20%), including 5 with intermediate scores who were reclassified as NK-LGLL; BMB supported the diagnosis in 2 additional cases, resulting in 57 NK-LGLL overall. These patients exhibited more cytopenias, higher treatment needs, and greater transfusion requirements than patients with alternative diagnoses. In the validation cohort (25 NK-LGLL and 32 reactive cases), CCL22 mutations were detected in 5 NK-LGLL (20%). Altogether, incorporation of CCL22 mutations reduced the fraction of unclassified patients, improved diagnostic sensitivity without compromising specificity, and may decrease reliance on invasive procedures. These revised international criteria represent a step toward standardized, molecularly guided NK-LGLL diagnosis.
- Open Access
- 13 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Supplemental methods, tables and figures
- 13 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Supplemental methods, tables and figures
- Open Access
- 13 June 2023
- Published by American Association for Cancer Research (AACR)
Data from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Purpose:This study aims to investigate the relationship between the intensity of the initial treatment given to patients with de novo diffuse large B-cell lymphoma (DLBCL) and the impact of their baseline cell-free DNA (cfDNA) levels on their long-term survival.Experimental Design:The GOELAMS 075 randomized clinical trial compared rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with high-dose R-chemotherapy plus autologous stem cell transplantation (R-HDT) for patients aged ≤60. An interim PET assessment was used to refer patients for salvage therapy. With a median follow-up of more than 5.8 years, we analyzed the effects of the treatment arm, salvage therapy, and cfDNA level at diagnosis on overall survival (OS).Results:In a representative group of 123 patients, a high cfDNA concentration (>55 ng/mL) at diagnosis was associated with poor clinical prognostic factors and constituted a prognostic marker, independently of the age-adjusted International Prognostic Index. A cfDNA level above a threshold value of 55 ng/mL at diagnosis was associated with significantly worse OS. In an intention-to-treat analysis, high-cfDNA R-CHOP patients (but not high-cfDNA R-HDT patients) had worse OS [HR (95% confidence interval), 3.99 (1.98–10.74); P = 0.006]. In patients with high cfDNA levels, salvage therapy and transplantation were associated with a significantly higher OS rate. Among 50 patients with complete response 6 months after the end of treatment, for 11 of 24 R-CHOP patients, the cfDNA did not fall back to normal values.Conclusions:In this randomized clinical trial, intensive regimens mitigated the negative influence of high cfDNA levels in de novo DLBCL, relative to R-CHOP.
- 13 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Purpose:This study aims to investigate the relationship between the intensity of the initial treatment given to patients with de novo diffuse large B-cell lymphoma (DLBCL) and the impact of their baseline cell-free DNA (cfDNA) levels on their long-term survival.Experimental Design:The GOELAMS 075 randomized clinical trial compared rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with high-dose R-chemotherapy plus autologous stem cell transplantation (R-HDT) for patients aged ≤60. An interim PET assessment was used to refer patients for salvage therapy. With a median follow-up of more than 5.8 years, we analyzed the effects of the treatment arm, salvage therapy, and cfDNA level at diagnosis on overall survival (OS).Results:In a representative group of 123 patients, a high cfDNA concentration (>55 ng/mL) at diagnosis was associated with poor clinical prognostic factors and constituted a prognostic marker, independently of the age-adjusted International Prognostic Index. A cfDNA level above a threshold value of 55 ng/mL at diagnosis was associated with significantly worse OS. In an intention-to-treat analysis, high-cfDNA R-CHOP patients (but not high-cfDNA R-HDT patients) had worse OS [HR (95% confidence interval), 3.99 (1.98–10.74); P = 0.006]. In patients with high cfDNA levels, salvage therapy and transplantation were associated with a significantly higher OS rate. Among 50 patients with complete response 6 months after the end of treatment, for 11 of 24 R-CHOP patients, the cfDNA did not fall back to normal values.Conclusions:In this randomized clinical trial, intensive regimens mitigated the negative influence of high cfDNA levels in de novo DLBCL, relative to R-CHOP.
- Open Access
- 13 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Supplemental methods, tables and figures
- 13 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Supplemental methods, tables and figures
- 4 May 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (7) , 1567-1571
Molecular mechanisms underlying transformation of large granular lymphocytic leukemia to high-grade T-cell lymphoma
- 4 May 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (7) , 1567-1571
Molecular mechanisms underlying transformation of large granular lymphocytic leukemia to high-grade T-cell lymphoma
- Open Access
- 2 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Supplemental methods, tables and figures
- 2 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Supplemental methods, tables and figures
- Open Access
- 2 May 2023
- Published by American Association for Cancer Research (AACR)
Data from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Purpose:This study aims to investigate the relationship between the intensity of the initial treatment given to patients with de novo diffuse large B-cell lymphoma (DLBCL) and the impact of their baseline cell-free DNA (cfDNA) levels on their long-term survival.Experimental Design:The GOELAMS 075 randomized clinical trial compared rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with high-dose R-chemotherapy plus autologous stem cell transplantation (R-HDT) for patients aged ≤60. An interim PET assessment was used to refer patients for salvage therapy. With a median follow-up of more than 5.8 years, we analyzed the effects of the treatment arm, salvage therapy, and cfDNA level at diagnosis on overall survival (OS).Results:In a representative group of 123 patients, a high cfDNA concentration (>55 ng/mL) at diagnosis was associated with poor clinical prognostic factors and constituted a prognostic marker, independently of the age-adjusted International Prognostic Index. A cfDNA level above a threshold value of 55 ng/mL at diagnosis was associated with significantly worse OS. In an intention-to-treat analysis, high-cfDNA R-CHOP patients (but not high-cfDNA R-HDT patients) had worse OS [HR (95% confidence interval), 3.99 (1.98–10.74); P = 0.006]. In patients with high cfDNA levels, salvage therapy and transplantation were associated with a significantly higher OS rate. Among 50 patients with complete response 6 months after the end of treatment, for 11 of 24 R-CHOP patients, the cfDNA did not fall back to normal values.Conclusions:In this randomized clinical trial, intensive regimens mitigated the negative influence of high cfDNA levels in de novo DLBCL, relative to R-CHOP.
- 2 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Purpose:This study aims to investigate the relationship between the intensity of the initial treatment given to patients with de novo diffuse large B-cell lymphoma (DLBCL) and the impact of their baseline cell-free DNA (cfDNA) levels on their long-term survival.Experimental Design:The GOELAMS 075 randomized clinical trial compared rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with high-dose R-chemotherapy plus autologous stem cell transplantation (R-HDT) for patients aged ≤60. An interim PET assessment was used to refer patients for salvage therapy. With a median follow-up of more than 5.8 years, we analyzed the effects of the treatment arm, salvage therapy, and cfDNA level at diagnosis on overall survival (OS).Results:In a representative group of 123 patients, a high cfDNA concentration (>55 ng/mL) at diagnosis was associated with poor clinical prognostic factors and constituted a prognostic marker, independently of the age-adjusted International Prognostic Index. A cfDNA level above a threshold value of 55 ng/mL at diagnosis was associated with significantly worse OS. In an intention-to-treat analysis, high-cfDNA R-CHOP patients (but not high-cfDNA R-HDT patients) had worse OS [HR (95% confidence interval), 3.99 (1.98–10.74); P = 0.006]. In patients with high cfDNA levels, salvage therapy and transplantation were associated with a significantly higher OS rate. Among 50 patients with complete response 6 months after the end of treatment, for 11 of 24 R-CHOP patients, the cfDNA did not fall back to normal values.Conclusions:In this randomized clinical trial, intensive regimens mitigated the negative influence of high cfDNA levels in de novo DLBCL, relative to R-CHOP.